Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer

Table 1 Major clinical characteristics related to primary EOC and its association with CD133 expression

Parameter	No. of patients (%)			P value
	CD133-negative expression	CD133-positive expression	Total
Age (yrs)				0.272
<60	10 (62.5)	6 (37.5)	16
> = 60	5 (38.5)	8 (61.5)	13
FIGO stage				1.000
1,2	2 (66.7)	1 (33.3)	3
3,4	13 (50.0)	13 (50.0)	26
Pathology of primary cancer				0.837†
Serous	8 (50.0)	8 (50.0)	16
Mucinous	2 (100)	0 (0)	2
Endometrioid	1 (50.0)	1 (50.0)	2
Clear cell	1 (100)	0 (0)	1
Mixed epithelial	2 (40.0)	3 (60.0)	5
Undifferentiated	1 (66.7)	2 (33.3)	3
Histological grade*				0.640
1,2	3 (60.0)	2 (40.0)	5
3,	8 (44.4)	10 (55.6)	18
Extent of surgical resection				0.477
TAH + BSO	13 (56.5)	10 (43.5)	23
Limited	2 (40.0)	3 (60.0)	5
Biopsy	0 (0)	1 (100)	1
Lymph node metastasis				0.812
Yes	9 (50.0)	9 (50.0)	18
No	6 (54.5)	5 (45.5)	11
Ascites at the time of primary surgery				0.893
Yes	10 (52.6)	9 (47.4)	19
No	5 (50.0)	5 (50.0)	10
Adjuvant therapy				0.397
Chemotherapy	14 (56.0)	11 (44.0)	25
Chemotherapy + Radiotherapy	1 (66.7)	2 (33.3)	3
None	0 (0)	1 (100)	1
Platinum sensitivity				0.006
Sensitive	12 (75.0)	4 (25.0)	16
Resistant	2 (16.7)	10 (83.3)	12

Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-oophorectomy.
*Where data were available.
†P value was caculated by comparing serous vs. non-serous groups.

ISSN: 1471-2407